Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nerviano Medical Sciences

http://www.nervianoms.com/

Latest From Nerviano Medical Sciences

Merck KGaA Plumps For Reinvention To Refuel R&D

The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.

Business Strategies Oncology

Merck KGaA’s Oncology Sales And Pipeline Updates Dominate Q3 Earnings

The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.

Sales & Earnings Companies

Merck KGaA Joins Race To Develop Next-Gen PARP Inhibitors

PARP inhibitors have had great success in treating a number of cancers but the German major has placed a $65m bet that Nerviano's selective PARP1 approach could produce a safer and more efficacious option.

Cancer Deals
See All

Company Information

  • Other Names / Subsidiaries
    • NerPharMa
UsernamePublicRestriction

Register